Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants ≥18 years of age.
• Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy
• Provided informed consent to participate in the study
Locations
United States
Massachusetts
Analysis Group Inc.
RECRUITING
Boston
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2024-05-10
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 118
Treatments
Mavacamten
Adult participants with symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb